07.07.26 -- How Kodak Reimagined Its Film Infrastructure For Biopharma Manufacturing

Learn how risk-based studies, quality attributes, and proactive regulatory engagement support confident manufacturing transitions.

Uncover how our plant-based peptones support E. coli growth, plasmid yield, and controlled induction, offering a sustainable, animal-free alternative for biopharmaceutical cell culture.

A next‑gen single‑stranded DNA template improves non‑viral gene editing by boosting viability, knock‑in efficiency, delivery flexibility, and stability while overcoming limits of viral vectors.

Outsourced gene therapy programs suffer from fragmented, lagging visibility across CDMO networks, and a real-time integrated operating model unifies execution, governance, and risk data.

This comprehensive guide provides practical insights and best practices for ensuring the timely, secure, and reliable delivery of clinical trial materials worldwide.

Early research choices shape outcomes. Focusing on reproducibility, scalability, regulatory fit, and supply stability early cuts risk, prevents delays, and supports smoother development progress.

Opaque pricing slows decisions and erodes trust. Transparency clarifies cost drivers, improves budgeting, enables confident sourcing, and strengthens long-term R&D partnerships.

Assimilate how switching from LAL to rFC can enhance sustainability, improve testing reliability, and strengthen supply-chain resilience in endotoxin testing.

Watch as our CGT experts explore the evolving landscape of viral vector manufacturing, overcoming production bottlenecks, and the strategies necessary to bring life-changing therapies to more patients.

Accelerate access to high-quality, cost-effective lentiviral vectors with our manufacturing platform, delivering multi-fold yield improvements and scalable, space-efficient production.

Cryopreservation should be integrated across the entire supply chain to ensure traceability, reduce risk at handoffs, and support consistent, scalable therapy development and delivery.

In vivo CAR-T scales patient access and cuts timelines but turns biological hurdles into complex manufacturing demands. Precise assays and tight raw material controls are vital for regulatory success.

Discover how this Microbubble Cell Separation System outperformed standard magnetic methods in T cell recovery, speed, and scalability — achieving higher cell quality.